Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.

Cancer Reports
Suraj Pratap, Zhizhuang J Zhao

Abstract

Myeloid leukemia represents a heterogeneous group of cancers of blood and bone marrow which arise from clonal expansion of hematopoietic myeloid lineage cells. Acute myeloid leukemia (AML) has traditionally been treated with multi-agent chemotherapy, but conventional therapies have not improved the long-term survival for decades. Chronic myeloid leukemia (CML) is an indolent disease which requires lifelong treatment, is associated with significant side effects, and carries a risk of progression to potentially lethal blast crises. Recent advances in molecular biology, virology, and immunology have enabled researchers to grow and modify T lymphocytes ex-vivo. Chimeric antigen receptor (CAR) T-cell therapy has been shown to specifically target cells of lymphoid lineage and induce remission in acute lymphoblastic leukemia (ALL) patients. While the success of CAR T-cells against ALL is considered a defining moment in modern oncology, similar efficacy against myeloid leukemia cells remains elusive. Over the past 10 years, numerous CAR T-cells have been developed that can target novel myeloid antigens, and many clinical trials are finally starting to yield encouraging results. In this review, we present the recent advances in this fie...Continue Reading

References

Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·G GrossZ Eshhar
Jun 14, 2000·Chemical Immunology·M KonoplevaM Andreeff
Sep 18, 2001·American Journal of Hematology·R Paredes-AguileraS Nieto-Martinez
Jan 11, 2003·Archives of Pathology & Laboratory Medicine·Zahid KaleemGlenda White
May 19, 2007·Cancer Research·Amorette BarberCharles L Sentman
Jun 20, 2007·Proceedings of the National Academy of Sciences of the United States of America·Naoki HosenIrving L Weissman
Jul 5, 2008·Experimental Hematology·Amorette BarberCharles L Sentman
Apr 8, 2010·Science Translational Medicine·Yoriko SaitoFumihiko Ishikawa
Nov 30, 2010·Cell Stem Cell·Yoshikane KikushigeKoichi Akashi
May 5, 2011·The Journal of Clinical Investigation·Barbara SavoldoGianpietro Dotti
Oct 28, 2011·International Journal of Cancer. Journal International Du Cancer·Andreas A Hombach, Hinrich Abken
Jun 26, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Julia HilpertHelmut Rainer Salih
Jul 9, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·David S RitchieH Miles Prince
Jul 11, 2013·Molecular Therapy. Nucleic Acids·Zakaria GradaNabil Ahmed
Dec 18, 2013·Science Translational Medicine·Victor D FedorovMichel Sadelain
Sep 2, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Quan-Shun WangWei-Dong Han
Dec 7, 2014·Haematologica·Carol O'HearTerrence L Geiger
May 20, 2015·Expert Opinion on Biological Therapy·Markus Chmielewski, Hinrich Abken
Jul 6, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haruko TashiroMalcolm K Brenner
Oct 28, 2017·International Journal of Molecular Sciences·Eduardo LabordaTravis S Young

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved